### Significant Stock Transactions by Ionis Pharmaceuticals Executives Raise Eyebrows Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has recently seen notable stock transactions involving its executive vice president, Richard Geary. Over a span of just a few days, Geary executed multiple sales of the company's shares, totaling over $9 million. These transactions have sparked interest and speculation regarding the company's financial health and future prospects. - On November 6, 2025, Geary sold **33,038 shares** at an average price of **$75.72**, amounting to **$2,501,637.36** [https://baseballnewssource.com/2025/11/07/ionis-pharmaceuticals-nasdaqions-evp-richard-geary-sells-33038-shares/10915767.html]. - On November 5, 2025, he sold **1,601 shares** at **$75.01**, totaling **$120,091.01** [https://baseballnewssource.com/2025/11/07/richard-geary-sells-1601-shares-of-ionis-pharmaceuticals-nasdaqions-stock/10915841.html]. - On November 3, 2025, Geary sold **1,680 shares** for **$126,084.00** [https://baseballnewssource.com/2025/11/06/ionis-pharmaceuticals-nasdaqions-evp-sells-126084-00-in-stock/10912402.html]. - Additionally, on October 31, 2025, he sold **89,249 shares** for **$6,703,492.39** [https://www.themarketsdaily.com/2025/11/04/ionis-pharmaceuticals-nasdaqions-evp-richard-geary-sells-89249-shares.html]. ### Breakdown of Recent Stock Sales by Richard Geary 1. **Overview of Transactions**: - Richard Geary, EVP of Ionis Pharmaceuticals, has engaged in significant stock sales recently, indicating a strategic move possibly aligned with a pre-established trading plan. 2. **Transaction Details**: - **November 6, 2025**: Sold **33,038 shares** at **$75.72** for **$2,501,637.36**. - **November 5, 2025**: Sold **1,601 shares** at **$75.01** for **$120,091.01**. - **November 3, 2025**: Sold **1,680 shares** at **$75.05** for **$126,084.00**. - **October 31, 2025**: Sold **89,249 shares** at **$75.11** for **$6,703,492.39**. 3. **Ownership Post-Transactions**: - After these transactions, Geary retains **59,657 shares** in Ionis Pharmaceuticals, indicating continued investment in the company despite the sales [https://baseballnewssource.com/2025/11/07/richard-geary-sells-1601-shares-of-ionis-pharmaceuticals-nasdaqions-stock/10915841.html]. ### Supporting Data on Stock Transactions - **Total Shares Sold**: 125,568 shares - **Total Value of Transactions**: Approximately **$9,577,304.76** - **Average Sale Price**: Ranges from **$75.01 to $75.72** across different transactions. | Date | Shares Sold | Average Price | Total Value | |------------|-------------|---------------|----------------------| | Nov 6, 2025| 33,038 | $75.72 | $2,501,637.36 | | Nov 5, 2025| 1,601 | $75.01 | $120,091.01 | | Nov 3, 2025| 1,680 | $75.05 | $126,084.00 | | Oct 31, 2025| 89,249 | $75.11 | $6,703,492.39 | ### Conclusion: Implications of Geary's Stock Sales The recent stock sales by Richard Geary of Ionis Pharmaceuticals suggest a strategic financial maneuver, possibly influenced by market conditions or personal financial planning. 1. **Significant Sales**: Geary's total sales exceed **$9 million**, indicating a substantial liquidity event. 2. **Continued Ownership**: Despite the sales, Geary maintains a significant stake in the company, which may reflect confidence in Ionis Pharmaceuticals' future. 3. **Market Speculation**: These transactions could lead to speculation about the company's performance and future stock movements, as insider sales often attract investor attention. Overall, while the sales may raise questions, Geary's retained ownership suggests a commitment to the company's long-term success [https://transcriptdaily.com/2025/11/04/ionis-pharmaceuticals-nasdaqions-director-joseph-wender-sells-11200-shares-of-stock.html].